Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Thrombosis Journal
Published in: Thrombosis Journal 1/2024

Open Access 04-04-2024 | Interstitial Lung Disease and Pulmonary Fibrosis | Review

Under the dual effect of inflammation and pulmonary fibrosis, CTD-ILD patients possess a greater susceptibility to VTE

Published in: Thrombosis Journal | Issue 1/2024

Login to get access

Abstract

As an autoimmune disease, the persistent systemic inflammatory response associated with connective tissue disease (CTD) is involved in the development of venous thromboembolism (VTE). However, clinical data showed that the risk of VTE in patients differed between subtypes of CTD, suggesting that different subtypes may have independent mechanisms to promote the development of VTE, but the specific mechanism lacks sufficient research at present. The development of pulmonary fibrosis also contributes to the development of VTE, and therefore, patients with CTD-associated interstitial lung disease (CTD-ILD) may be at higher risk of VTE than patients with CTD alone or patients with ILD alone. In addition, the activation of the coagulation cascade response will drive further progression of the patient’s pre-existing pulmonary fibrosis, which will continue to increase the patient’s risk of VTE and adversely affect prognosis. Currently, the treatment for CTD-ILD is mainly immunosuppressive and antirheumatic therapy, such as the use of glucocorticoids and janus kinase-inhibitors (JAKis), but, paradoxically, these drugs are also involved in the formation of patients’ coagulation tendency, making the clinical treatment of CTD-ILD patients with a higher risk of developing VTE challenging. In this article, we review the potential risk factors and related mechanisms for the development of VTE in CTD-ILD patients to provide a reference for clinical treatment and prevention.
Literature
1.
Hoyles RK, Khan K, Shiwen X, Howat SL, Lindahl GE, Leoni P, du Bois RM, Wells AU, Black CM, Abraham DJ, Denton CP. Fibroblast-specific perturbation of transforming growth factor beta signaling provides insight into potential pathogenic mechanisms of scleroderma-associated lung fibrosis - exaggerated response to alveolar epithelial injury in a novel mouse model. Arthritis Rheum. 2008;58:1175–88.CrossRefPubMed
2.
3.
Dhooria S, Sehgal IS, Agarwal R, Muthu V, Prasad KT, Kathirvel S, Garg M, Bal A, Aggarwal AN, Behera D. Incidence, prevalence, and national burden of interstitial lung diseases in India: estimates from two studies of 3089 subjects. PLoS ONE. 2022;17:e0271665.CrossRefPubMedPubMedCentral
4.
Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, Huisman MV, Humbert M, Jennings CS, Jimenez D et al. 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): the Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Respir J 2019; 54.
5.
Galanaud JP, Monreal M, Kahn SR. Epidemiology of the post-thrombotic syndrome. Thromb Res. 2018;164:100–9.CrossRefPubMed
6.
Raskob GE, Angchaisuksiri P, Blanco AN, Buller H, Gallus A, Hunt BJ, Hylek EM, Kakkar TL, Konstantinides SV, McCumber M, et al. Thrombosis: a major contributor to global disease burden. Semin Thromb Hemost. 2014;40:724–35.CrossRefPubMed
7.
Sogaard KK, Schmidt M, Pedersen L, Horvath-Puho E, Sorensen HT. 30-year mortality after venous thromboembolism: a population-based cohort study. Circulation. 2014;130:829–36.CrossRefPubMed
8.
Law Y, Chan YC, Cheng SWK. Epidemiological updates of venous thromboembolism in a Chinese population. Asian J Surg. 2018;41:176–82.CrossRefPubMed
9.
Zhang Z, Lei J, Shao X, Dong F, Wang J, Wang D, Wu S, Xie W, Wan J, Chen H, et al. Trends in hospitalization and In-Hospital mortality from VTE, 2007 to 2016, in China. Chest. 2019;155:342–53.CrossRefPubMed
10.
Hyldgaard C, Bendstrup E, Pedersen AB, Pedersen L, Ellingsen T. Interstitial lung disease in connective tissue diseases: survival patterns in a Population-based cohort. J Clin Med 2021; 10.
11.
Luo Q, Xie J, Han Q, Tang C, Chen X, Wu L, Chen R. Prevalence of venous thromboembolic events and diagnostic performance of the wells score and revised geneva scores for pulmonary embolism in patients with interstitial lung disease: a prospective study. Heart Lung Circ. 2014;23:778–85.CrossRefPubMed
12.
Sun H, Liu M, Yang X, Xi L, Xu W, Deng M, Ren Y, Xie W, Dai H, Wang C. Incidence and risk factors of venous thrombotic events in patients with interstitial lung disease during hospitalization. Thromb J. 2023;21:17.CrossRefPubMedPubMedCentral
13.
Riva N, Donadini MP, Ageno W. Epidemiology and pathophysiology of venous thromboembolism: similarities with atherothrombosis and the role of inflammation. Thromb Haemost. 2015;113:1176–83.CrossRefPubMed
14.
Ramagopalan SV, Wotton CJ, Handel AE, Yeates D, Goldacre MJ. Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: record-linkage study. BMC Med. 2011;9:1.CrossRefPubMedPubMedCentral
15.
Yusuf HR, Hooper WC, Grosse SD, Parker CS, Boulet SL, Ortel TL. Risk of venous thromboembolism occurrence among adults with selected autoimmune diseases: a study among a U.S. cohort of commercial insurance enrollees. Thromb Res. 2015;135:50–7.CrossRefPubMed
16.
Molander V, Bower H, Frisell T, Askling J. Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden. Ann Rheum Dis. 2021;80:169–75.CrossRefPubMed
17.
Guibert F, Garnier AS, Wacrenier S, Piccoli G, Djema A, Gansey R, Demiselle J, Brilland B, Cousin M, Besson V et al. Patients with ANCA-Associated Glomerulonephritis and connective tissue diseases: a comparative study from the Maine-Anjou AAV Registry. J Clin Med 2019; 8.
18.
Xu J, Lupu F, Esmon CT. Inflammation, innate immunity and blood coagulation. Hamostaseologie. 2010;30:5–.CrossRefPubMed
19.
Saghazadeh A, Hafizi S, Rezaei N. Inflammation in venous thromboembolism: cause or consequence? Int Immunopharmacol. 2015;28:655–65.CrossRefPubMed
20.
Wang Y, Golden JB, Fritz Y, Zhang X, Diaconu D, Camhi MI, Gao H, Dawes SM, Xing X, Ganesh SK, et al. Interleukin 6 regulates psoriasiform inflammation-associated thrombosis. JCI Insight. 2016;1:e89384.CrossRefPubMedPubMedCentral
21.
Grimnes G, Isaksen T, Tichelaar Y, Brox J, Braekkan SK, Hansen JB. C-reactive protein and risk of venous thromboembolism: results from a population-based case-crossover study. Haematologica. 2018;103:1245–50.CrossRefPubMedPubMedCentral
22.
Zoller B, Li X, Sundquist J, Sundquist K. Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden. Lancet. 2012;379:244–9.CrossRefPubMed
23.
Habe K, Wada H, Higashiyama A, Akeda T, Tsuda K, Mori R, Kakeda M, Matsumoto T, Ohishi K, Yamanaka K, et al. The plasma levels of ADAMTS-13, Von Willebrand Factor, VWFpp, and fibrin-related markers in patients with systemic sclerosis having thrombosis. Clin Appl Thromb Hemost. 2018;24:920–7.CrossRefPubMed
24.
Habe K, Wada H, Higashiyama A, Akeda T, Tsuda K, Mori R, Kakeda M, Yamanaka K, Mizutani H. Elevated plasma D-dimer levels in dermatomyositis patients with cutaneous manifestations. Sci Rep. 2019;9:1410.CrossRefPubMedPubMedCentral
25.
Sener S, Basaran O, Lacinel Gurlevik S, Kaya Akca U, Atalay E, Kasap Cuceoglu M, Balik Z, Batu ED, Bilginer Y, Ozsurekci Y, Ozen S. Challenges in diagnosing COVID-19 related disease in pediatric patients with rheumatic disease. Mod Rheumatol. 2022;32:1108–13.CrossRefPubMed
26.
Wang F, Liu J, Fang Y, Wen J, He M, Han Q, Li X. Hypercoagulability in rheumatoid arthritis: a bibliometric analysis and Retrospective Data Mining Study. ACS Omega. 2023;8:48522–34.CrossRefPubMedPubMedCentral
27.
Habe K, Wada H, Mizutani K, Matsushima Y, Kondo M, Yamanaka K. The clinical significance of a shortened activated partial thromboplastin time in patients with connective tissue disease. Clin Rheumatol. 2021;40:4675–83.CrossRefPubMed
28.
Qiang F, Xu H, Sheng J. Relationship between plasma fibrinogen degradation products(FDP) and D-dimer levels and disease activity in rheumatoid arthritis: a STROBE compliant article. Med (Baltim). 2022;101:e30455.CrossRef
29.
Xue L, Tao L, Li X, Wang Y, Wang B, Zhang Y, Gao N, Dong Y, Xu N, Xiong C, et al. Plasma fibrinogen, D-dimer, and fibrin degradation product as biomarkers of rheumatoid arthritis. Sci Rep. 2021;11:16903.CrossRefPubMedPubMedCentral
30.
Martis N, Jamme M, Bagnis-Isnard C, Pouteil-Noble C, Presne C, Vigneau C, Grange S, Burtey S, Coindre JP, Wynckel A, et al. Systemic autoimmune disorders associated with thrombotic microangiopathy: a cross-sectional analysis from the French National TMA registry: systemic autoimmune disease-associated TMA. Eur J Intern Med. 2021;93:78–86.CrossRefPubMed
31.
Murdaca G, Colombo BM, Cagnati P, Gulli R, Spano F, Puppo F. Endothelial dysfunction in rheumatic autoimmune diseases. Atherosclerosis. 2012;224:309–17.CrossRefPubMed
32.
Setiadi H, Yago T, Liu Z, McEver RP. Endothelial signaling by neutrophil-released oncostatin M enhances P-selectin-dependent inflammation and thrombosis. Blood Adv. 2019;3:168–83.CrossRefPubMedPubMedCentral
33.
Bugala K, Mazurek A, Gryga K, Komar M, Kopec G, Musial J, Podolec P, Perricone C, Plazak W. Influence of autoimmunity and inflammation on endothelial function and thrombosis in systemic lupus erythematosus patients. Clin Rheumatol. 2018;37:2087–93.CrossRefPubMed
34.
Meng Y, Yin Q, Ma Q, Qin H, Zhang J, Zhang B, Pang H, Tian H. FXII regulates the formation of deep vein thrombosis via the PI3K/AKT signaling pathway in mice. Int J Mol Med 2021; 47.
35.
Levi M, van der Poll T, Buller HR. Bidirectional relation between inflammation and coagulation. Circulation. 2004;109:2698–704.CrossRefPubMed
36.
Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol. 2013;13:34–45.CrossRefPubMed
37.
38.
Koupenova M, Clancy L, Corkrey HA, Freedman JE. Circulating platelets as mediators of immunity, inflammation, and thrombosis. Circul Res. 2018;122:337–51.CrossRef
39.
Bowie EJ, Solberg LA Jr., Fass DN, Johnson CM, Knutson GJ, Stewart ML, Zoecklein LJ. Transplantation of normal bone marrow into a pig with severe Von Willebrand’s disease. J Clin Invest. 1986;78:26–30.CrossRefPubMedPubMedCentral
40.
41.
Malik RA, Zhou J, Fredenburgh JC, Truong TK, Crosby JR, Revenko AS, Weitz JI. Polyphosphate-induced thrombosis in mice is factor XII dependent and is attenuated by histidine-rich glycoprotein. Blood Adv. 2021;5:3540–51.CrossRefPubMedPubMedCentral
42.
Frangou E, Chrysanthopoulou A, Mitsios A, Kambas K, Arelaki S, Angelidou I, Arampatzioglou A, Gakiopoulou H, Bertsias GK, Verginis P, et al. REDD1/autophagy pathway promotes thromboinflammation and fibrosis in human systemic lupus erythematosus (SLE) through NETs decorated with tissue factor (TF) and interleukin-17A (IL-17A). Ann Rheum Dis. 2019;78:238–48.CrossRefPubMed
43.
Wang Y, Luo L, Braun OO, Westman J, Madhi R, Herwald H, Morgelin M, Thorlacius H. Neutrophil extracellular trap-microparticle complexes enhance thrombin generation via the intrinsic pathway of coagulation in mice. Sci Rep. 2018;8:4020.CrossRefPubMedPubMedCentral
44.
Mazetto BM, Hounkpe BW, da Silva Saraiva S, Vieira-Damiani G, Dos Santos APR, Jacinto BC, Vaz CO, Mesquita GTV, Annichino-Bizzacchi JM, De Paula EV, Orsi FA. Association between neutrophil extracellular traps (NETs) and thrombosis in antiphospholipid syndrome. Thromb Res. 2022;214:132–7.CrossRefPubMed
45.
Arroyo AB, Fernandez-Perez MP, Del Monte A, Aguila S, Mendez R, Hernandez-Antolin R, Garcia-Barber N, de Reyes-Garcia L, Gonzalez-Jimenez AM, Arcas P. miR-146a is a pivotal regulator of neutrophil extracellular trap formation promoting thrombosis. Haematologica. 2021;106:1636–46.CrossRefPubMed
46.
Le Mao R, Ropars T, Tromeur C, Barnier A, Hourmant B, Guegan M, Jimenez D, Leroyer C, Lacut K, Couturaud F. Risk of recurrent venous thromboembolism and bleeding in patients with interstitial lung disease: a cohort study. J Thromb Thrombolysis. 2022;53:67–73.CrossRefPubMed
47.
Reyes-Jimenez E, Ramirez-Hernandez AA, Santos-Alvarez JC, Velazquez-Enriquez JM, Pina-Canseco S, Baltierrez-Hoyos R, Vasquez-Garzon VR. Involvement of 4-hydroxy-2-nonenal in the pathogenesis of pulmonary fibrosis. Mol Cell Biochem. 2021;476:4405–19.CrossRefPubMed
48.
Hernandez-Rodriguez NA, Cambrey AD, Harrison NK, Chambers RC, Gray AJ, Southcott AM, duBois RM, Black CM, Scully MF, McAnulty RJ, et al. Role of thrombin in pulmonary fibrosis. Lancet. 1995;346:1071–3.CrossRefPubMed
49.
Strehl C, Spies CM, Buttgereit F. Pharmacodynamics of glucocorticoids. Clin Exp Rheumatol. 2011;29:S13–18.PubMed
50.
Johannesdottir SA, Horvath-Puho E, Dekkers OM, Cannegieter SC, Jorgensen JOL, Ehrenstein V, Vandenbroucke JP, Pedersen L, Sorensen HT. Use of glucocorticoids and risk of venous thromboembolism a Nationwide Population-based case-control study. Clin Otolaryngol. 2013;38:379–379.CrossRef
51.
Ueda T, Sakagami T, Kikuchi T, Takada T. Mycophenolate mofetil as a therapeutic agent for interstitial lung diseases in systemic sclerosis. Respir Investig. 2018;56:14–20.CrossRefPubMed
52.
Maher TM, Tudor VA, Saunders P, Gibbons MA, Fletcher SV, Denton CP, Hoyles RK, Parfrey H, Renzoni EA, Kokosi M, et al. Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial. Lancet Respir Med. 2023;11:45–54.CrossRefPubMed
53.
Rotrosen ET, Zahedi Niaki O, Kassamali B, Lonowski S, Shahriari N, LaChance A, Vleugels RA. Intravenous immunoglobulin and Dermatomyositis-Associated venous thromboembolism. JAMA Dermatol. 2023;159:666–7.CrossRefPubMed
54.
Isidori AM, Minnetti M, Sbardella E, Graziadio C, Grossman AB. Mechanisms in endocrinology: the spectrum of haemostatic abnormalities in glucocorticoid excess and defect. Eur J Endocrinol. 2015;173:R101–113.CrossRefPubMed
55.
Oray M, Abu Samra K, Ebrahimiadib N, Meese H, Foster CS. Long-term side effects of glucocorticoids. Expert Opin Drug Saf. 2016;15:457–65.CrossRefPubMed
56.
Coelho MC, Santos CV, Vieira Neto L, Gadelha MR. Adverse effects of glucocorticoids: coagulopathy. Eur J Endocrinol. 2015;173:M11–21.CrossRefPubMed
57.
Mimori T, Nakashima R, Hosono Y. Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment. Curr Rheumatol Rep. 2012;14:264–74.CrossRefPubMed
58.
Sholter DE, Armstrong PW. Adverse effects of corticosteroids on the cardiovascular system. Can J Cardiol. 2000;16:505–11.PubMed
59.
McLornan DP, Pope JE, Gotlib J, Harrison CN. Current and future status of JAK inhibitors. Lancet. 2021;398:803–16.CrossRefPubMed
60.
Mease P, Charles-Schoeman C, Cohen S, Fallon L, Woolcott J, Yun H, Kremer J, Greenberg J, Malley W, Onofrei A, et al. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data. Ann Rheum Dis. 2020;79:1400–13.CrossRefPubMed
61.
Molander V, Bower H, Frisell T, Delcoigne B, Di Giuseppe D, Askling J, group As. Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis. Ann Rheum Dis 2022.
62.
Yates M, Mootoo A, Adas M, Bechman K, Rampes S, Patel V, Qureshi S, Cope AP, Norton S, Galloway JB. Venous thromboembolism risk with JAK inhibitors: a Meta-analysis. Arthritis Rheumatol. 2021;73:779–88.CrossRefPubMed
63.
Verden A, Dimbil M, Kyle R, Overstreet B, Hoffman KB. Analysis of spontaneous Postmarket Case reports submitted to the FDA regarding thromboembolic adverse events and JAK inhibitors. Drug Saf. 2018;41:357–61.CrossRefPubMed
64.
Miyakawa Y, Oda A, Druker BJ, Miyazaki H, Handa M, Ohashi H, Ikeda Y. Thrombopoietin induces tyrosine phosphorylation of Stat3 and Stat5 in human blood platelets. Blood. 1996;87:439–46.CrossRefPubMed
65.
He M, Pawar A, Desai RJ, Glynn RJ, Lee H, Weinblatt ME, Solomon DH, Kim SC. Risk of venous thromboembolism associated with methotrexate versus hydroxychloroquine for rheumatoid arthritis: a propensity score-matched cohort study. Semin Arthritis Rheum. 2021;51:1242–50.CrossRefPubMed
66.
Jin T, Bokarewa M, Amu S, Tarkowski A. Impact of short-term therapies with biologics on prothrombotic biomarkers in rheumatoid arthritis. Clin Exp Rheumatol. 2009;27:491–4.PubMed
67.
Setyawan J, Mu F, Yarur A, Zichlin ML, Yang H, Fernan C, Billmyer E, Downes N, Azimi N, Strand V. Risk of thromboembolic events and Associated Risk Factors, including treatments, in patients with Immune-mediated diseases. Clin Ther. 2021;43:1392–e14071391.CrossRefPubMed
68.
Liang H, Danwada R, Guo D, Curtis JR, Kilpatrick RD, Hendrickson B, Islam SS. Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the association with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world setting. RMD Open. 2019;5:e001013.CrossRefPubMedPubMedCentral
69.
Alsilmi R. The prevalence of pulmonary embolism in patients with interstitial lung disease: a cross-sectional retrospective study. Cureus. 2022;14:e23063.PubMedPubMedCentral
70.
Evrard SM, d’Audigier C, Mauge L, Israel-Biet D, Guerin CL, Bieche I, Kovacic JC, Fischer AM, Gaussem P, Smadja DM. The profibrotic cytokine transforming growth factor-beta1 increases endothelial progenitor cell angiogenic properties. J Thromb Haemost. 2012;10:670–9.CrossRefPubMed
71.
Phillips RJ, Burdick MD, Hong K, Lutz MA, Murray LA, Xue YY, Belperio JA, Keane MP, Strieter RM. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest. 2004;114:438–46.CrossRefPubMedPubMedCentral
72.
Smadja DM, Dorfmuller P, Guerin CL, Bieche I, Badoual C, Boscolo E, Kambouchner M, Cazes A, Mercier O, Humbert M, et al. Cooperation between human fibrocytes and endothelial colony-forming cells increases angiogenesis via the CXCR4 pathway. Thromb Haemost. 2014;112:1002–13.CrossRefPubMedPubMedCentral
73.
Smadja DM. Vasculogenic stem and progenitor cells in Human: future cell therapy product or Liquid Biopsy for Vascular Disease. Adv Exp Med Biol. 2019;1201:215–37.CrossRefPubMed
74.
Alvarado-Moreno JA, Hernandez-Lopez R, Chavez-Gonzalez A, Yoder MC, Rangel-Corona R, Isordia-Salas I, Hernandez-Juarez J, Cerbulo-Vazquez A, Gonzalez-Jimenez MA, Majluf-Cruz A. Endothelial colony-forming cells: Biological and functional abnormalities in patients with recurrent, unprovoked venous thromboembolic disease. Thromb Res. 2016;137:157–68.CrossRefPubMed
75.
Billoir P, Blandinieres A, Gendron N, Chocron R, Gunther S, Philippe A, Guerin CL, Israel-Biet D, Smadja DM. Endothelial colony-forming cells from idiopathic pulmonary fibrosis patients have a high Procoagulant potential. Stem Cell Reviews Rep. 2021;17:694–9.CrossRef
76.
Billoir P, Miranda S, Damian L, Richard V, Benhamou Y, Le Cam Duchez V. Development of a thrombin generation test in cultured endothelial cells: evaluation of the prothrombotic effects of antiphospholipid antibodies. Thromb Res. 2018;169:87–92.CrossRefPubMed
77.
Sprunger DB, Olson AL, Huie TJ, Fernandez-Perez ER, Fischer A, Solomon JJ, Brown KK, Swigris JJ. Pulmonary fibrosis is associated with an elevated risk of thromboembolic disease. Eur Respir J. 2012;39:125–32.CrossRefPubMed
78.
Lin C, von der Thusen J, Daalhuisen J, ten Brink M, Crestani B, van der Poll T, Borensztajn K, Spek CA. Protease-activated receptor (PAR)-2 is required for PAR-1 signalling in pulmonary fibrosis. J Cell Mol Med. 2015;19:1346–56.CrossRefPubMedPubMedCentral
79.
Atanelishvili I, Liang J, Akter T, Spyropoulos DD, Silver RM, Bogatkevich GS. Thrombin increases lung fibroblast survival while promoting alveolar epithelial cell apoptosis via the endoplasmic reticulum stress marker, CCAAT enhancer-binding homologous protein. Am J Respir Cell Mol Biol. 2014;50:893–902.CrossRefPubMedPubMedCentral
80.
Bruzova M, Pavlova M, Matej R, Sterclova M, Vasakova M. Interstitial score and concentrations of IL-4Ralpha, PAR-2, and MMP-7 in Bronchoalveolar Lavage Fluid could be useful markers for distinguishing idiopathic interstitial pneumonias. Diagnostics (Basel). 2021; 11.
81.
Wygrecka M, Kwapiszewska G, Jablonska E, von Gerlach S, Henneke I, Zakrzewicz D, Guenther A, Preissner KT, Markart P. Role of protease-activated receptor-2 in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183:1703–14.CrossRefPubMed
82.
Silver RM, Wilson DA, Akter T, Atanelishvili I, Huggins JT, Kajdasz K, Highland KB, Nietert PJ, Bogatkevich GS. Safety and Tolerability of Thrombin Inhibition in Scleroderma-Associated interstitial lung disease. ACR Open Rheumatol. 2019;1:403–11.CrossRefPubMedPubMedCentral
83.
Smadja DM, Mauge L, Nunes H, d’Audigier C, Juvin K, Borie R, Carton Z, Bertil S, Blanchard A, Crestani B, et al. Imbalance of circulating endothelial cells and progenitors in idiopathic pulmonary fibrosis. Angiogenesis. 2013;16:147–57.CrossRefPubMed
84.
King CS, Freiheit E, Brown AW, Shlobin OA, Aryal S, Ahmad K, Khangoora V, Flaherty KR, Venuto D, Nathan SD. Association between Anticoagulation and Survival in Interstitial Lung Disease An Analysis of the Pulmonary Fibrosis Foundation Patient Registry. Chest. 2021;159:1507–16.CrossRefPubMed
85.
Zhang Q, Zhang X, Zhang J, Jiang M, Zhang Y, Zheng D, Wu L, Wang W, Wang B, Wang Y. Genetic association and causal inference between lung function and venous thromboembolism. Respir Res. 2023;24:36.CrossRefPubMedPubMedCentral
86.
Gupta N, Zhao YY, Evans CE. The stimulation of thrombosis by hypoxia. Thromb Res. 2019;181:77–83.CrossRefPubMed
87.
Gupta N, Sahu A, Prabhakar A, Chatterjee T, Tyagi T, Kumari B, Khan N, Nair V, Bajaj N, Sharma M, Ashraf MZ. Activation of NLRP3 inflammasome complex potentiates venous thrombosis in response to hypoxia. Proc Natl Acad Sci U S A. 2017;114:4763–8.CrossRefPubMedPubMedCentral
88.
89.
Ninivaggi M, Swieringa F, Middelveld H, Schmalschlager V, Roest M, de Laat-Kremers R, de Laat B. Exercise and hypoxia-induced hypercoagulability is counterbalanced in women in part by decreased platelet reactivity. Thromb Res. 2024;234:142–50.CrossRefPubMed
90.
Cameron SJ, Mix DS, Ture SK, Schmidt RA, Mohan A, Pariser D, Stoner MC, Shah P, Chen L, Zhang H, et al. Hypoxia and ischemia promote a maladaptive platelet phenotype. Arterioscler Thromb Vasc Biol. 2018;38:1594–606.CrossRefPubMedPubMedCentral
91.
Tyagi T, Ahmad S, Gupta N, Sahu A, Ahmad Y, Nair V, Chatterjee T, Bajaj N, Sengupta S, Ganju L, et al. Altered expression of platelet proteins and calpain activity mediate hypoxia-induced prothrombotic phenotype. Blood. 2014;123:1250–60.CrossRefPubMed
92.
Khanna D, Tashkin DP, Denton CP, Renzoni EA, Desai SR, Varga J, Etiology. Risk factors, and biomarkers in systemic sclerosis with interstitial lung disease. Am J Respir Crit Care Med. 2020;201:650–60.CrossRefPubMedPubMedCentral
93.
Ng KH, Chen DY, Lin CH, Chao WC, Chen YM, Chen YH, Huang WN, Hsieh TY, Lai KL, Tang KT, Chen HH. Risk of interstitial lung disease in patients with newly diagnosed systemic autoimmune rheumatic disease: a nationwide, population-based cohort study. Semin Arthritis Rheum. 2020;50:840–5.CrossRefPubMed
94.
Johnson SR, Hakami N, Ahmad Z, Wijeysundera DN. Venous thromboembolism in systemic sclerosis: prevalence, risk factors, and Effect on Survival. J Rheumatol. 2018;45:942–6.CrossRefPubMed
95.
Chung WS, Lin CL, Sung FC, Hsu WH, Yang WT, Lu CC, Kao CH. Systemic sclerosis increases the risks of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study. Rheumatology (Oxford). 2014;53:1639–45.CrossRefPubMed
96.
Schoenfeld SR, Choi HK, Sayre EC, Avina-Zubieta JA. Risk of pulmonary embolism and deep venous thrombosis in systemic sclerosis: a General Population-based study. Arthritis Care Res (Hoboken). 2016;68:246–53.CrossRefPubMed
97.
Furtado S, Dunogue B, Jourdi G, Chaigne B, Chibah A, Legendre P, Mouthon L. High D-dimer plasma concentration in systemic sclerosis patients: prevalence and association with vascular complications. J Scleroderma Relat Disord. 2021;6:178–86.CrossRefPubMed
98.
Kuszmiersz P, Pacholczak-Madej R, Siwiec A, Celinska-Lowenhoff M, Iwaniec T, Kosalka-Wegiel J, Zareba L, Bazan-Socha S, Dropinski J. Thrombin generation potential is enhanced in systemic sclerosis: impact of selected endothelial biomarkers. Clin Exp Rheumatol. 2021;39(Suppl 131):13–9.CrossRefPubMed
99.
El Hasbani G, Viola M, Sciascia S, Taher AT, Uthman I. Antiphospholipid antibodies in Inflammatory and Autoimmune Rheumatic and Musculoskeletal diseases Beyond Lupus: a systematic review of the available evidence. Rheumatol Ther. 2021;8:81–94.CrossRefPubMedPubMedCentral
100.
Li L, Lu N, Avina-Galindo AM, Zheng Y, Lacaille D, Esdaile JM, Choi HK, Avina-Zubieta JA. The risk and trend of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: a general population-based study. Rheumatology (Oxford). 2021;60:188–95.CrossRefPubMed
101.
Holmqvist ME, Neovius M, Eriksson J, Mantel A, Wallberg-Jonsson S, Jacobsson LT, Askling J. Risk of venous thromboembolism in patients with rheumatoid arthritis and association with disease duration and hospitalization. JAMA. 2012;308:1350–6.CrossRefPubMed
102.
Mori S, Soejima H, Hokamaki J, Tsujita K. Clinical disease activity is a major determinant of plasma D-dimer elevation in outpatients with rheumatoid arthritis: a hospital-based cross-sectional study. Mod Rheumatol 2023.
103.
Dai Y, Wang W, Yu Y, Hu S. Rheumatoid arthritis-associated interstitial lung disease: an overview of epidemiology, pathogenesis and management. Clin Rheumatol. 2021;40:1211–20.CrossRefPubMed
104.
Westerlind H, Kastbom A, Ronnelid J, Hansson M, Alfredsson L, Mathsson-Alm L, Serre G, Cornillet M, Holmdahl R, Skriner K, et al. The association between autoantibodies and risk for venous thromboembolic events among patients with rheumatoid arthritis. Rheumatology (Oxford). 2023;62:2106–12.CrossRefPubMed
105.
Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, Wells PS, Gould MK, Dentali F, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141:eS419–96.CrossRef
106.
Wei J, Li W, Pei Y, Shen Y, Li J. Clinical analysis of preoperative risk factors for the incidence of deep venous thromboembolism in patients undergoing posterior lumbar interbody fusion. J Orthop Surg Res. 2016;11:68.CrossRefPubMedPubMedCentral
107.
Wong LE, Bass AR. Postoperative risk of venous thromboembolism in rheumatic disease patients. Curr Rheumatol Rep. 2015;17:11.CrossRefPubMed
108.
Niki Y, Matsumoto H, Hakozaki A, Mochizuki T, Momohara S. Rheumatoid arthritis: a risk factor for deep venous thrombosis after total knee arthroplasty? Comparative study with osteoarthritis. J Orthop Sci. 2010;15:57–63.CrossRefPubMed
109.
Kuo CF, See LC, Yu KH, Chou IJ, Chang HC, Chiou MJ, Luo SF. Incidence, cancer risk and mortality of dermatomyositis and polymyositis in Taiwan: a nationwide population study. Br J Dermatol. 2011;165:1273–9.CrossRefPubMed
110.
Fathi M, Vikgren J, Boijsen M, Tylen U, Jorfeldt L, Tornling G, Lundberg IE. Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum. 2008;59:677–85.CrossRefPubMed
111.
Cho SK, Kim H, Myung J, Nam E, Jung SY, Jang EJ, Yoo DH, Sung YK. Incidence and prevalence of idiopathic inflammatory myopathies in Korea: a Nationwide Population-based study. J Korean Med Sci. 2019;34:e55.CrossRefPubMedPubMedCentral
112.
Marie I, Hatron PY, Dominique S, Cherin P, Mouthon L, Menard JF. Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Arthritis Rheum. 2011;63:3439–47.CrossRefPubMed
113.
Ji SY, Zeng FQ, Guo Q, Tan GZ, Tang HF, Luo YJ, Tang ZQ, Han YF. Predictive factors and unfavourable prognostic factors of interstitial lung disease in patients with polymyositis or dermatomyositis: a retrospective study. Chin Med J (Engl). 2010;123:517–22.CrossRefPubMed
114.
Carruthers EC, Choi HK, Sayre EC, Avina-Zubieta JA. Risk of deep venous thrombosis and pulmonary embolism in individuals with polymyositis and dermatomyositis: a general population-based study. Ann Rheum Dis. 2016;75:110–6.CrossRefPubMed
115.
Antovic A, Notarnicola A, Svensson J, Lundberg IE, Holmqvist M. Venous thromboembolic events in idiopathic inflammatory myopathy: occurrence and relation to Disease Onset. Arthritis Care Res (Hoboken). 2018;70:1849–55.CrossRefPubMed
116.
Chung WS, Lin CL, Sung FC, Lu CC, Kao CH. Increased risk of venous thromboembolism in patients with dermatomyositis/polymyositis: a nationwide cohort study. Thromb Res. 2014;134:622–6.CrossRefPubMed
117.
Notarnicola A, Barsotti S, Nasman L, Tang Q, Holmqvist M, Lundberg IE, Antovic A. Evaluation of risk factors and biomarkers related to arterial and venous thrombotic events in idiopathic inflammatory myopathies. Scand J Rheumatol. 2021;50:390–7.CrossRefPubMed
118.
Moghadam-Kia S, Oddis CV, Sato S, Kuwana M, Aggarwal R. Anti-melanoma differentiation-Associated Gene 5 is Associated with Rapidly Progressive Lung Disease and Poor Survival in US patients with amyopathic and Myopathic Dermatomyositis. Arthritis Care Res (Hoboken). 2016;68:689–94.CrossRefPubMed
119.
Tsuji H, Nakashima R, Hosono Y, Imura Y, Yagita M, Yoshifuji H, Hirata S, Nojima T, Sugiyama E, Hatta K, et al. Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, Tacrolimus, and Cyclophosphamide in interstitial lung diseases accompanied by Anti-melanoma differentiation-Associated Gene 5-Positive Dermatomyositis. Arthritis Rheumatol. 2020;72:488–98.CrossRefPubMed
120.
Palm O, Garen T, Berge Enger T, Jensen JL, Lund MB, Aalokken TM, Gran JT. Clinical pulmonary involvement in primary Sjogren’s syndrome: prevalence, quality of life and mortality–a retrospective study based on registry data. Rheumatology (Oxford). 2013;52:173–9.CrossRefPubMed
121.
Chung WS, Lin CL, Sung FC, Hsu WH, Chen YF, Kao CH. Increased risks of deep vein thrombosis and pulmonary embolism in Sjogren syndrome: a nationwide cohort study. J Rheumatol. 2014;41:909–15.CrossRefPubMed
122.
Avina-Zubieta JA, Jansz M, Sayre EC, Choi HK. The risk of deep venous thrombosis and pulmonary embolism in primary Sjogren Syndrome: a General Population-based study. J Rheumatol. 2017;44:1184–9.CrossRefPubMedPubMedCentral
123.
Mofors J, Holmqvist M, Westermark L, Bjork A, Kvarnstrom M, Forsblad-d’Elia H, Magnusson Bucher S, Eriksson P, Theander E, Mandl T, et al. Concomitant Ro/SSA and La/SSB antibodies are biomarkers for the risk of venous thromboembolism and cerebral infarction in primary Sjogren’s syndrome. J Intern Med. 2019;286:458–68.CrossRefPubMedPubMedCentral
124.
Yao WC, Leong KH, Chiu LT, Chou PY, Wu LC, Chou CY, Kuo CF, Tsai SY. The trends in the incidence and thrombosis-related comorbidities of antiphospholipid syndrome: a 14-year nationwide population-based study. Thromb J. 2022;20:50.CrossRefPubMedPubMedCentral
125.
Fauchais AL, Lambert M, Launay D, Michon-Pasturel U, Queyrel V, Nguyen N, Hebbar M, Hachulla E, Devulder B, Hatron PY. Antiphospholipid antibodies in primary Sjogren’s syndrome: prevalence and clinical significance in a series of 74 patients. Lupus. 2004;13:245–8.CrossRefPubMed
126.
Pasoto SG, Chakkour HP, Natalino RR, Viana VS, Bueno C, Lianza AC, de Andrade JL, Neto ML, Fuller R, Bonfa E. Lupus anticoagulant: a marker for stroke and venous thrombosis in primary Sjogren’s syndrome. Clin Rheumatol. 2012;31:1331–8.CrossRefPubMed
127.
Habe K, Wada H, Matsumoto T, Ohishi K, Ikejiri M, Matsubara K, Morioka T, Kamimoto Y, Ikeda T, Katayama N, Mizutani H. Presence of Antiphospholipid Antibodies as a risk factor for thrombotic events in patients with connective tissue diseases and Idiopathic Thrombocytopenic Purpura. Intern Med. 2016;55:589–95.CrossRefPubMed
128.
129.
Mageau A, Borie R, Crestani B, Timsit JF, Papo T, Sacre K. Epidemiology of interstitial lung disease in systemic lupus erythematosus in France: a nation-wide population-based study over 10 years. Respirology. 2022;27:630–4.CrossRefPubMedPubMedCentral
130.
Avina-Zubieta JA, Vostretsova K, De Vera MA, Sayre EC, Choi HK. The risk of pulmonary embolism and deep venous thrombosis in systemic lupus erythematosus: a general population-based study. Semin Arthritis Rheum. 2015;45:195–201.CrossRefPubMedPubMedCentral
131.
Kishore S, Jatwani S, Malhotra B, Lirette ST, Mittal V, Majithia V. Systemic Lupus Erythematosus is Associated with a high risk of venous thromboembolism in hospitalized patients leading to poor outcomes and a higher cost: results from Nationwide Inpatient Sample database 2003–2011. ACR Open Rheumatol. 2019;1:194–200.CrossRefPubMedPubMedCentral
132.
Brouwer JL, Bijl M, Veeger NJ, Kluin-Nelemans HC, van der Meer J. The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus. Blood. 2004;104:143–8.CrossRefPubMed
133.
134.
Hinojosa-Azaola A, Romero-Diaz J, Vargas-Ruiz AG, Nunez-Alvarez CA, Cicero-Casarrubias A, Ocampo-Torres MC, Sanchez-Guerrero J. Venous and arterial thrombotic events in systemic Lupus Erythematosus. J Rheumatol. 2016;43:576–86.CrossRefPubMed
135.
Toloza SM, Uribe AG, McGwin G Jr., Alarcon GS, Fessler BJ, Bastian HM, Vila LM, Wu R, Shoenfeld Y, Roseman JM, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum. 2004;50:3947–57.CrossRefPubMed
136.
Lin JA, Liao CC, Lee YJ, Wu CH, Huang WQ, Chen TL. Adverse outcomes after major surgery in patients with systemic lupus erythematosus: a nationwide population-based study. Ann Rheum Dis. 2014;73:1646–51.CrossRefPubMed
137.
Zoller B, Svensson PJ, Dahlback B, Lind-Hallden C, Hallden C, Elf J. Genetic risk factors for venous thromboembolism. Expert Rev Hematol. 2020;13:971–81.CrossRefPubMed
138.
Juul K, Tybjaerg-Hansen A, Mortensen J, Lange P, Vestbo J, Nordestgaard BG. Factor V leiden homozygosity, dyspnea, and reduced pulmonary function. Arch Intern Med. 2005;165:2032–6.CrossRefPubMed
139.
Eichinger S, Weltermann A, Mannhalter C, Minar E, Bialonczyk C, Hirschl M, Schonauer V, Lechner K, Kyrle PA. The risk of recurrent venous thromboembolism in heterozygous carriers of factor V Leiden and a first spontaneous venous thromboembolism. Arch Intern Med. 2002;162:2357–60.CrossRefPubMed
140.
Juul K, Tybjaerg-Hansen A, Schnohr P, Nordestgaard BG. Factor V Leiden and the risk for venous thromboembolism in the adult Danish population. Ann Intern Med. 2004;140:330–7.CrossRefPubMed
141.
Regeczy N, Balogh I, Lakos G, Zeher M, Bodolay E, Szucs G, Kiss E, Ajzner E, Szegedi G. Hypercoagulability in various autoimmune diseases: no association with factor V Leiden mutation. Haematologia (Budap). 2000;30:35–9.CrossRefPubMed
142.
Tagalakis V, Patenaude V, Kahn SR, Suissa S. Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE study cohort. Am J Med. 2013;126:e832813–821.CrossRef
143.
Jayasinghe P, Wickramasinghe N, Krishnakumar P, Sadikeen A, Fernando A. Characteristics of Connective Tissue Diseases Associated Interstitial Lung Diseases - a single centre study in Sri Lanka. Ceylon Med J. 2021;66:38–43.CrossRefPubMed
144.
Lowe GD, Rumley A, Woodward M, Morrison CE, Philippou H, Lane DA, Tunstall-Pedoe H. Epidemiology of coagulation factors, inhibitors and activation markers: the third Glasgow MONICA Survey. I. illustrative reference ranges by age, sex and hormone use. Br J Haematol. 1997;97:775–84.CrossRefPubMed
145.
Cohen HJ, Harris T, Pieper CF. Coagulation and activation of inflammatory pathways in the development of functional decline and mortality in the elderly. Am J Med. 2003;114:180–7.CrossRefPubMed
146.
Yildiz O. Vascular smooth muscle and endothelial functions in aging. Ann N Y Acad Sci. 2007;1100:353–60.CrossRefPubMed
147.
Tagalakis V, Kondal D, Ji Y, Boivin JF, Moride Y, Ciampi A, Kahn SR. Men had a higher risk of recurrent venous thromboembolism than women: a large population study. Gend Med. 2012;9:33–43.CrossRefPubMed
148.
Eichinger S, Hron G, Bialonczyk C, Hirschl M, Minar E, Wagner O, Heinze G, Kyrle PA. Overweight, obesity, and the risk of recurrent venous thromboembolism. Arch Intern Med. 2008;168:1678–83.CrossRefPubMed
Metadata
Title
Under the dual effect of inflammation and pulmonary fibrosis, CTD-ILD patients possess a greater susceptibility to VTE
Publication date
04-04-2024

Other articles of this Issue 1/2024

Thrombosis Journal 1/2024 Go to the issue

Research

Association between antithrombotic therapy and mortality in patients hospitalized for COVID‑19

Research

Thrombosis-related characteristics of pregnant women with antithrombin deficiency, protein C deficiency and protein S deficiency in Japan

Research

Risk factors for peripherally inserted central catheter-related venous thrombosis in adult patients with cancer

Research

Renal damage and old age: risk factors for thrombosis in patients with ANCA-associated vasculitis

Review

Oxidative stress in acute pulmonary embolism: emerging roles and therapeutic implications

Case Report

Spontaneous coronary artery dissection in a young patient with antiphospholipid syndrome

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits